In line with these observations, the combined administration of imiquimod, FLT3L and a peptide-based vaccine not only increased the number of peptide-specific CD8+ T cells but also prompted the mobilization of cDCs and pDCs in melanoma patients (207). Here, CD8A is linked to melanoma.